Stiefel Laboratories acquires Barrier Therapeutics

Upon the closing of the acquisition, all remaining outstanding shares of Barrier common stock, other than those held by stockholders who properly perfect appraisal rights under Delaware law, were converted into the right to receive $4.15 per share in cash.

The acquisition of Barrier is said to broaden Stiefel’s product offering with three premium prescription products, making a wider range of treatment options available to physicians and patients under the Stiefel umbrella. It also deepens Stiefel pipeline of products by adding several promising product candidates.

In addition to bringing new assets to Stiefel, the acquisition also provides the opportunity for the company to leverage its global footprint for the newly-acquired portfolio. The global headquarters of Stiefel Laboratories will remain in Coral Gables, Florida and the marketing and sales headquarters will remain in Duluth, Georgia.

Charles Stiefel, chairman and CEO of Stiefel Laboratories, said: “The acquisition reinforces Stiefel’s promise to provide novel, high-quality, safe and effective products for the treatment of skin diseases and our continued and enthusiastic commitment to advancing the field of dermatology.”